Patent Oppositions in medicinal compounds for specific treatments industry

Explore the competitive field of medicinal compounds for specific treatments where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in medicinal compounds for specific treatments technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the medicinal compounds for specific treatments industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the medicinal compounds for specific treatments industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Jul 16, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Methods Of Treating Chronic Kidney Disease With DapagliflozinASTRAZENECAJun 17, 2026CAMULON
Methods Of Treating Chronic Kidney Disease With DapagliflozinASTRAZENECAJun 16, 2026BRAND MURRAY FULLER
Methods Of Treating Chronic Kidney Disease With DapagliflozinASTRAZENECAJun 11, 2026DEVA HOLDING ANONIM SIRKETI
Drug Delivery Systems And Methods For Treatment Of Bladder Cancer With GemcitabineTARIS BIOMEDICALJun 10, 2026GRUND GROUP PATENTANWALTE UND SOLICITOR PARTG MBB
Method Of Synthesizing Thyroid Hormone Analogs And Polymorphs ThereofMADRIGAL PHARMACEUTICALSJun 10, 2026EGIS
Methods Of Treating Chronic Kidney Disease With DapagliflozinASTRAZENECAJun 9, 2026BULLE DR
Method Of Synthesizing Thyroid Hormone Analogs And Polymorphs ThereofMADRIGAL PHARMACEUTICALSJun 9, 2026KRAUS & LEDERER PARTGMBB
Method Of Synthesizing Thyroid Hormone Analogs And Polymorphs ThereofF HOFFMANN LA ROCHEJun 8, 2026BOTTI & FERRARI
Pharmaceutical Formulation Comprising EzetimibeASSIA CHEMICAL INDUSTRIESJun 3, 2026VENNER SHIPLEY
Use Of Ahr Agonist For The Preventive Or Curative Treatment Of Metabolic Syndrome And The Associated DisordersINSTITUT NATIONAL DE RECHERCHE POUR LAGRICULTUREJun 3, 2026FUCHS

To stay ahead in the competitive medicinal compounds for specific treatments industry, companies are constantly innovating. Here are the top patents facing oppositions in the medicinal compounds for specific treatments industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Jul 16, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Oct 12, 2022S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS26
Apr 14, 2021Methods And Compositions For Treating CancerJANSSEN ONCOLOGY24
Nov 6, 2024Dosing Regimen Associated With Long Acting Injectable Paliperidone EstersJANSSEN PHARMACEUTICA23
Oct 23, 2024New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTIS20
Oct 11, 2023New UseNOVARTIS19
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM19
Mar 8, 2023Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTIS18
Aug 6, 2025Use Of Long-Acting Glp-1 PeptidesNOVO NORDISK18
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofAMGEN EUROPE17
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelAVENTIS PHARMA15